Eurofins Scientific SE Stock
Stocks
ERF
FR0014000MR3
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Euronext Paris
11:55:00 2026-09-03 am EDT
|
After hours 12:36:51 pm | |||
| 73.46 EUR | +0.93% |
|
73.40 | -0.08% |
| Aug. 24 | Wall Street's Three-Way Stress Test |  |
| Jul. 23 | Eurofins Scientific SE, H1 2026 Earnings Call, Jul 23, 2026 |
| Market Cap | 12.63B 14.68B 11.86B 10.85B 20.25B 1,388B 20.41B 140B 54.62B 709B 55.14B 53.94B 2,285B | P/E 2026 * |
24.3x | P/E 2027 * | 19.2x |
|---|---|---|---|---|---|
| Enterprise Value | 15.98B 18.58B 15B 13.72B 25.61B 1,756B 25.82B 177B 69.1B 897B 69.76B 68.24B 2,890B | EV / Sales 2026 * |
2.11x | EV / Sales 2027 * | 1.95x |
| Free-Float |
60.39% | Yield 2026 * |
1.11% | Yield 2027 * | 1.26% |
| Markets | Quality | ||
|---|---|---|---|
Euronext Paris
| ERF | Real-time | |
CBOE
| Real-time | ||
|
Tradegate
| ESF0 | Real-time | |
|
Xetra
| ESF0 | Delayed | |
|
Börse Stuttgart
| ESF0 | Delayed | |
|
OTC Markets
| ERFSF | Delayed | |
|
London S.E.
| 0MV5 | Delayed | |
|
CBOE
| 0MV5 | Real-time | |
|
Boerse Muenchen
| ESF0 | Real-time | |
|
Deutsche Boerse AG
| ESF0 | Delayed | |
|
Wiener Boerse
| ESF | End-of-day quote | |
|
Borsa Italiana
| 4ERF | End-of-day quote |
Last Transcript : Eurofins Scientific SE
| 1 day | +0.93% | ||
| 1 week | +0.63% | ||
| Current month | +1.27% | ||
| 1 month | +8.44% | ||
| 3 months | +18.91% | ||
| 6 months | +11.10% | ||
| Current year | +17.72% |
| 1 week | 71.1 |  | 74.78 |
| 1 month | 67.8 | | 74.78 |
| Current year | 56.84 | | 74.78 |
| 1 year | 54.86 | | 74.78 |
| 3 years | 39.47 | | 74.78 |
| 5 years | 39.47 | | 127.68 |
| 10 years | 29.82 | | 127.68 |
| Manager | Title | Age | Since |
|---|---|---|---|
Gilles Martin
CEO | Chief Executive Officer | 63 | 1986-12-31 |
Laurent Lebras
DFI | Director of Finance/CFO | - | 2014-12-31 |
Christian Wurst
PRN | Corporate Officer/Principal | 54 | 2019-09-30 |
| Director | Title | Age | Since |
|---|---|---|---|
Gilles Martin
CHM | Chairman | 63 | 1986-12-31 |
Yves-Loïc Martin
BRD | Director/Board Member | 60 | 2014-12-31 |
Valérie Hanote
BRD | Director/Board Member | 60 | 1989-12-31 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 4/27/26 | Buy | 700 | 0.0004% | |||
| 4/19/26 | Sell | Chief Financial Officer | 3,000 | 0.0016% | ||
| 4/19/26 | Exercice | Executive/Senior Manager | 700 | 0.0004% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.93% | +0.63% | +16.86% | +29.29% | 14.65B | |
| -0.24% | -1.09% | +2.00% | +17.50% | 50.14B | |
| +1.34% | -4.38% | +431.69% | +527.65% | 44.85B | |
| +0.70% | +1.11% | +43.70% | +20.11% | 43.43B | |
| +0.09% | -2.76% | +7.72% | +76.83% | 41.14B | |
| +0.43% | -3.26% | +14.75% | +49.08% | 32.92B | |
| -0.19% | +7.82% | - | - | 17.56B | |
| -0.48% | -3.32% | +22.87% | +123.04% | 16.55B | |
| -0.80% | -2.45% | +78.12% | +41.53% | 13.93B | |
| +1.80% | -4.31% | -9.78% | -37.21% | 12.33B | |
| Average | +0.33% | -1.23% | +67.55% | +94.20% | 28.75B | |
| Weighted average by Cap. | +0.32% | -1.31% | +88.00% | +121.42% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 7.59B 8.82B 7.12B 6.52B 12.16B 834B 12.26B 84.24B 32.81B 426B 33.12B 32.4B 1,372B | 8.01B 9.31B 7.52B 6.88B 12.84B 880B 12.94B 88.91B 34.63B 450B 34.96B 34.19B 1,448B |
| Net income | 531M 617M 498M 456M 851M 58.33B 858M 5.89B 2.3B 29.81B 2.32B 2.27B 96B | 660M 767M 619M 566M 1.06B 72.48B 1.07B 7.32B 2.85B 37.04B 2.88B 2.82B 119B |
| Net Debt | 3.35B 3.89B 3.14B 2.88B 5.37B 368B 5.41B 37.18B 14.48B 188B 14.62B 14.3B 606B | 3.01B 3.5B 2.83B 2.59B 4.83B 331B 4.87B 33.45B 13.03B 169B 13.15B 12.87B 545B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-09-03 | €73.46 | +0.93% | 307,393 |
| 26-09-02 | €72.78 | +1.70% | 228,096 |
| 26-09-01 | €71.56 | -1.35% | 247,022 |
| 26-08-31 | €72.54 | +0.25% | 520,172 |
| 26-08-28 | €72.36 | -0.88% | 275,066 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ERF Stock
Select your edition
All financial news and data tailored to specific country editions
